Alzheimer's trial closure impacts IXICO

Digital technologies company IXICO has received notification from one of its pharmaceutical clients of its decision to stop the screening, randomisation and dosing in a Phase II/III clinical study in Alzheimer's disease in which IXICO is providing specialist imaging clinical trial services, it announced on Tuesday.